Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › abiraterone

abiraterone

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of abiraterone

66 trials tracked of abiraterone: 11 in phase 3 or 4 and 7 with published results. The most-cited published study has 395 citations.

66Trials tracked
11Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 2 Phase 3 9 Phase 2 50 Phase 1 2 Other / NA 3
  1. Phase 3 Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms Completed · 395 cited
  2. Phase 3 Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer Completed · 326 cited
  3. Phase 4 Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients Completed · 171 cited
  4. Phase 3 Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) Completed · 131 cited
  5. Phase 3 Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) Completed · 91 cited
  6. Phase 4 Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Completed · 65 cited
Show 44 more trials
  1. Phase 3 A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) Completed · 29 cited
  2. Phase 3 A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy Completed
  3. Phase 3 A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Completed
  4. Phase 3 Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Completed
  5. Phase 3 Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer Completed
  6. Phase 2 Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. Completed
  7. Phase 2 Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy Completed
  8. Phase 2 A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy Completed
  9. Phase 2 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer Completed
  10. Phase 2 Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer Completed
  11. Phase 2 Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy Completed
  12. Phase 2 A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer Completed
  13. Phase 2 AASUR in High Risk Prostate Cancer Completed
  14. Phase 2 Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT Completed
  15. Phase 2 Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Completed
  16. Phase 2 RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) Completed
  17. Phase 2 Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Completed
  18. Phase 2 Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer Completed
  19. Phase 2 CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone Completed
  20. Phase 2 Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer Completed
  21. Phase 2 Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer Completed
  22. Phase 2 ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer Completed
  23. Phase 2 Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer Completed
  24. Phase 2 Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide Completed
  25. Phase 2 An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Completed
  26. Phase 2 A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer Completed
  27. Phase 2 Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer Completed
  28. Phase 2 Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer Completed
  29. Phase 2 Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies Completed
  30. Phase 2 Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy Completed
  31. Phase 2 Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer Completed
  32. Phase 2 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Completed
  33. Phase 2 An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Completed
  34. Phase 2 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate Completed
  35. Phase 2 Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer Completed
  36. Phase 2 Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Completed
  37. Phase 2 Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy Completed
  38. Phase 2 An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma Completed
  39. Phase 2 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer Completed
  40. Phase 2 AMG 386 and Abiraterone for Advanced Prostate Cancer Completed
  41. Phase 2 Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer Completed
  42. Phase 2 A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy Completed
  43. Phase 2 A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients Completed
  44. Phase 2 Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy Completed

Showing the 50 most-cited and recently-updated of 66 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer
Oncology RCT
PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer Low PSA at 24 weeks predicts longer survival in prostate cancer
This post-hoc analysis of five phase 3 trials in 7129 patients with prostate cancer found that 96-month overall survival varied by metastati…
Men with prostate cancer who hit a PSA level of 0.2 ng/mL or less within 24 weeks of starting treatment are far more likely to survive at le…
May 1, 2026
Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC
Drug Pipeline Cohort
Niraparib plus abiraterone and prednisone shows mixed results in HRR-mutated mCRPC New drug combo extends life for some prostate cancer patients
This retrospective cohort study of 5 patients with HRR-mutated metastatic castration-resistant prostate cancer evaluated niraparib plus abir…
Some men with advanced prostate cancer are living longer with a powerful new drug combo, even when they’re older or too weak for harsh treat…
Frontiers Apr 28, 2026
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression
Oncology RCT
Deutenzalutamide improves rPFS in mCRPC after abiraterone and docetaxel progression New Pill Slows Advanced Prostate Cancer After Other Drugs Fail
A randomized phase III trial in 417 patients with metastatic castration-resistant prostate cancer after progression on or intolerance to abi…
A new daily pill slowed advanced prostate cancer progression by 42 percent in men whose disease grew despite standard hormone therapy and ch…
Apr 15, 2026